Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Dalong Zhu (), Weimin Wang, Guoyu Tong, Guoqing Ma, Jianhua Ma, Jie Han, Xin Zhang, Yang Liu, Shenglian Gan, Hong Qin, Qing Zheng, Jing Ning, Zhiyi Zhu, Mengying Guo, Yue Bu, Yao Li, Catherine L. Jones, Martijn Fenaux, Mohammed K. Junaidi, Susan Xu and Hai Pan ()
Additional contact information
Dalong Zhu: Affiliated Hospital of Nanjing University Medical School
Weimin Wang: Affiliated Hospital of Nanjing University Medical School
Guoyu Tong: Affiliated Hospital of Nanjing University Medical School
Guoqing Ma: The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Jianhua Ma: Nanjing First Hospital
Jie Han: CNPC Central Hospital
Xin Zhang: Liaoyou Gem Flower Hospital
Yang Liu: Daqing People’s Hospital
Shenglian Gan: Changde First People’s Hospital
Hong Qin: Hangzhou Sciwind Biosciences
Qing Zheng: Hangzhou Sciwind Biosciences
Jing Ning: Hangzhou Sciwind Biosciences
Zhiyi Zhu: Hangzhou Sciwind Biosciences
Mengying Guo: Hangzhou Sciwind Biosciences
Yue Bu: Hangzhou Sciwind Biosciences
Yao Li: Hangzhou Sciwind Biosciences
Catherine L. Jones: Sciwind Biosciences
Martijn Fenaux: Sciwind Biosciences
Mohammed K. Junaidi: Sciwind Biosciences
Susan Xu: Sciwind Biosciences
Hai Pan: Hangzhou Sciwind Biosciences

Nature Communications, 2024, vol. 15, issue 1, 1-11

Abstract: Abstract Glucagon-like peptide-1 (GLP-1) analogs are important therapeutics for type 2 diabetes and obesity. Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog. We conducted a Phase 2, randomized, double-blind, placebo-controlled study enrolling 145 adults with T2DM. Participants were randomized to 0.4, 0.8, or 1.2 mg ecnoglutide or placebo as once-weekly injections for 20 weeks. The primary objective was to evaluate the efficacy of ecnoglutide, as measured by HbA1c change from baseline at Week 20. Secondary endpoints included body weight, glucose and lipid parameters, as well as safety. We show that, at end of treatment, the 0.4, 0.8, and 1.2 mg groups had statistically significant HbA1c reductions from baseline of −1.81%, −1.90%, and −2.39%, respectively, compared to −0.55% for placebo (P

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52353-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52353-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52353-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().